ポスター：AAV製造の上流工程およびプロデューサー細胞株の特性評価における次世代シーケンス（NGS）データ解析の自動化

April 16, 2026

Ensuring the quality and safety of gene and cell therapies (CGTs) that employ Adeno‑Associated Virus (AAV) as a vector becomes increasingly important as demand for novel therapeutics grows. Adhering to emerging regulatory guidelines, mitigating risk, and standardizing assays throughout the characterization of starting materials, cell line development, cell line characterization, and AAV vector quality control (QC) is essential. To address this need, biopharmaceutical companies are adopting next‑generation sequencing (NGS) to characterize critical components used in AAV upstream manufacturing. 

Using NGS for cell line characterization and vector assessment offers numerous benefits, including comprehensive genomic analysis, high accuracy, and faster results than traditional methods. However, overcoming the challenge of manual handling of large amounts of NGS data and its analysis is necessary to fully utilize these benefits. Implementing robust automation of NGS workflows to streamline data analysis into a consistent, well‑managed process from start to finish is essential for long‑term success in AAV upstream manufacturing. 

Genedata Selector^® is an enterprise software platform that automates and accelerates complex NGS data analysis workflows in-house to ensure seamless CGTs development